DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Brazikumab
Brazikumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
The Two Tontti Tudiul Lui Hi Ha Unit
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
List Item PDCO Monthly Report of Opinions on Paediatric Investigation
TNF-Anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages Via an Fc-Dependent Mechanism
The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
Inflammatory Bowel Disease: Current Treatment Strategies Edward V
New Targets in Inflammatory Bowel Disease Therapy: 2021
(INN) for Biological and Biotechnological Substances
H1 2020 Results
Dissecting the Heterogeneity in T-Cell Mediated Inflammation In
Strategies to Obtain Diverse and Specific Human Monoclonal
H1 2021 Results Clinical Trials Appendix PDF 2769KB
Top View
PDF of Antibody News
Filed by Astrazeneca PLC This Communication Is Filed Pursuant to Rule 425 Under the United States Securities Act of 1933 Subject Company: Alexion Pharmaceuticals, Inc
PDCO Minutes of the 7-10 November 2017 Meeting
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Financial Statements
Etiology and Management of Lack Or Loss of Response to Anti–Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Disease
Kinase Inhibition in Autoimmunity and Inflammation
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Choosing and Positioning Biologic Therapy for Crohn's Disease
Novel and Emerging Therapies for Inflammatory Bowel Disease
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
IL12/23 Or Selective IL23 Inhibition for the Management of Moderate-To-Severe Crohn's Disease?
Astrazeneca Recovery of Global Rights to Brazikumab (MEDI2070) from Allergan Completed
Respiratory & Immunology: Near- Term Opportunities
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
Clinical Trials Appendix Q1 2021 Results Update
Recent Updates on the Basic Mechanisms and Pathogenesis of Inflammatory Bowel Diseases in Experimental Animal Models
(INN-Nimet) 15.6.2020
MEDI2070) from Allergan
Diverse Threads in IBD Clinical Development
Emerging Therapies for Inflammatory Bowel Disease
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Clinical Trials Appendix H1 2020 Results Update Movement Since Q1 2020 Update
Inflammatory Bowel Disease: a Panel Discussion on Clinical and Operational Strategies for Biologic Usage
Filed by Astrazeneca PLC This Communication Is Filed Pursuant to Rule 425 Under the United States Securities Act of 1933 Subject Company: Alexion Pharmaceuticals, Inc
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
JAK Inhibitors and the Next Wave of Oral Small Molecules in the Management of IBD